共查询到20条相似文献,搜索用时 0 毫秒
1.
Rubinstein J 《The New England journal of medicine》2005,353(6):627-30; author reply 627-30
2.
Zimetbaum P 《The New England journal of medicine》2007,356(9):935-941
3.
Rehman Hu 《The New England journal of medicine》2007,356(23):2424-6; author reply 2424-6
4.
Twenty-seven patients with atrial fibrillation without any concomitant conduction abnormality have been treated with oral amiodarone in a daily maintenance dose of 200 mg. The drug has been used for three purposes: 1) to block atrioventricular conduction, thereby decreasing the ventricular rate during atrial fibrillation (9 patients), 2) as prophylaxis against paroxysmal atrial fibrillation (8 patients), 3) as prophylaxis against recurrence of atrial fibrillation after DC conversion to sinus rhythm (13 patients). All patients were considered refractory to other antiarrhythmic drugs in these respects. In the second group, 4 of the 8 patients reported complete cessation of attacks and the others a marked reduction of the attack rate. In the third group, 10 of the 13 patients have maintained sinus rhythm for a longer period on treatment with amiodarone than with other drugs, resulting more than a triple prolongation of the time in sinus rhythm. In 3 patients the drug has been discontinued because of side-effects. In conclusion, amiodarone affords protection from episodes of paroxysmal atrial fibrillation, as well as from recurrence of atrial fibrillation after DC conversion to sinus rhythm. If the drug is ineffective in either of these respects, it may still be useful as a means of moderating the ventricular response in atrial fibrillation. 相似文献
5.
Meininghaus DG Langes K Spehn J 《The New England journal of medicine》2002,347(5):368-70; author reply 368-70
6.
Amiodarone to prevent recurrence of atrial fibrillation 总被引:45,自引:0,他引:45
Aggarwal A 《The New England journal of medicine》2000,343(8):578-9; author reply 579-80
7.
Knecht S O'Neill MD Verbeet T 《The New England journal of medicine》2008,359(14):1522; author reply 1522
8.
Simini B 《The New England journal of medicine》2012,366(1):88-9; author reply 89-90
9.
Pearson S Troughton R Richards AM 《The New England journal of medicine》2011,365(24):2333-4; author reply 2335
10.
11.
Granger CB Alexander JH McMurray JJ Lopes RD Hylek EM Hanna M Al-Khalidi HR Ansell J Atar D Avezum A Bahit MC Diaz R Easton JD Ezekowitz JA Flaker G Garcia D Geraldes M Gersh BJ Golitsyn S Goto S Hermosillo AG Hohnloser SH Horowitz J Mohan P Jansky P Lewis BS Lopez-Sendon JL Pais P Parkhomenko A Verheugt FW Zhu J Wallentin L;ARISTOTLE Committees Investigators 《The New England journal of medicine》2011,365(11):981-992
12.
Roy D Talajic M Nattel S Wyse DG Dorian P Lee KL Bourassa MG Arnold JM Buxton AE Camm AJ Connolly SJ Dubuc M Ducharme A Guerra PG Hohnloser SH Lambert J Le Heuzey JY O'Hara G Pedersen OD Rouleau JL Singh BN Stevenson LW Stevenson WG Thibault B Waldo AL;Atrial Fibrillation Congestive Heart Failure Investigators 《The New England journal of medicine》2008,358(25):2667-2677
13.
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators 总被引:24,自引:0,他引:24
Roy D Talajic M Dorian P Connolly S Eisenberg MJ Green M Kus T Lambert J Dubuc M Gagné P Nattel S Thibault B 《The New England journal of medicine》2000,342(13):913-920
BACKGROUND: The restoration and maintenance of sinus rhythm is a desirable goal in patients with atrial fibrillation, because the prevention of recurrences can improve cardiac function and relieve symptoms. Uncontrolled studies have suggested that amiodarone in low doses may be more effective and safer than other agents in preventing recurrence, but this agent has not been tested in a large, randomized trial. METHODS: We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone. We randomly assigned patients who had had at least one episode of atrial fibrillation within the previous six months to amiodarone or to sotalol or propafenone, given in an open-label fashion. The patients in the group assigned to sotalol or propafenone underwent a second randomization to determine whether they would receive sotalol or propafenone first; if the first drug was unsuccessful the second agent was prescribed. Loading doses of the drugs were administered and electrical cardioversion was performed (if necessary) within 21 days after randomization for all patients in both groups. The follow-up period began 21 days after randomization. The primary end point was the length of time to a first recurrence of atrial fibrillation. RESULTS: Of the 403 patients in the study, 201 were assigned to amiodarone and 202 to either sotalol (101 patients) or propafenone (101 patients). After a mean of 16 months of follow-up, 71 of the patients who were assigned to amiodarone (35 percent) and 127 of those who were assigned to sotalol or propafenone (63 percent) had a recurrence of atrial fibrillation (P<0.001). Adverse events requiring the discontinuation of drug therapy occurred in 18 percent of the patients receiving amiodarone, as compared with 11 percent of those treated with sotalol or propafenone (P=0.06). CONCLUSIONS: Amiodarone is more effective than sotalol or propafenone for the prevention of recurrences of atrial fibrillation. 相似文献
14.
Rubin SA 《The New England journal of medicine》2000,342(4):289-290
15.
16.
17.
18.
19.
20.
MacDonald MR McMurray JJ Petrie MC 《The New England journal of medicine》2012,366(11):1058-9; author reply 1060-1